Advances in Stem Cell-Based Therapies for Neonatal Hypoxic-Ischemic Encephalopathy: A Comprehensive Review

Abstract

Neonatal hypoxic-ischemic encephalopathy (NHIE) remains a leading cause of neonatal morbidity and mortality, often resulting in long-term neurological impairments. This review explores the potential of stem cell therapy as an emerging treatment for NHIE, focusing on recent advances in human pluripotent stem cells (hPSCs) and mesenchymal stem cells (MSCs). These stem cells are particularly promising due to their immunomodulatory properties and ability to secrete bioactive factors that promote tissue repair and regeneration. Research suggests that stem cell therapy can facilitate neural repair through various mechanisms, including engraftment, differentiation into mature neural cells, secretion of paracrine factors, and stimulation of endogenous neurogenesis. Moreover, stem cells exhibit anti-apoptotic effects and reduce inflammation and oxidative stress in damaged brain tissues. However, challenges such as immunocompatibility, control of differentiation, and long-term safety remain significant barriers to clinical translation. This article also examines the potential of combining stem cell therapy with therapeutic hypothermia (TH), which is currently the standard of care for NHIE, to improve treatment outcomes. Emerging technologies, including gene editing and personalized medicine, offer promising prospects for the future of NHIE treatment. Despite the challenges, stem cell therapy holds substantial potential as a pivotal strategy for treating NHIE, contingent upon further research and clinical trials.